These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 15123848)

  • 1. Effect of medical comorbidity on response to fluoxetine augmentation or dose increase in outpatients with treatment-resistant depression.
    Perlis RH; Iosifescu DV; Alpert J; Nierenberg AA; Rosenbaum JF; Fava M
    Psychosomatics; 2004; 45(3):224-9. PubMed ID: 15123848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and sociodemographic predictors of response to augmentation, or dose increase among depressed outpatients resistant to fluoxetine 20 mg/day.
    Perlis RH; Alpert J; Nierenberg AA; Mischoulon D; Yeung A; Rosenbaum JF; Fava M
    Acta Psychiatr Scand; 2003 Dec; 108(6):432-8. PubMed ID: 14616224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes.
    Barbosa L; Berk M; Vorster M
    J Clin Psychiatry; 2003 Apr; 64(4):403-7. PubMed ID: 12716240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment approaches to major depressive disorder relapse. Part 1: dose increase.
    Schmidt ME; Fava M; Zhang S; Gonzales J; Raute NJ; Judge R
    Psychother Psychosom; 2002; 71(4):190-4. PubMed ID: 12097783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes and genome-wide association for a brain methylation site in an antidepressant pharmacogenetics study in Mexican Americans.
    Wong ML; Dong C; Flores DL; Ehrhart-Bornstein M; Bornstein S; Arcos-Burgos M; Licinio J
    Am J Psychiatry; 2014 Dec; 171(12):1297-309. PubMed ID: 25220861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Residual symptoms in depressed patients who respond acutely to fluoxetine.
    Nierenberg AA; Keefe BR; Leslie VC; Alpert JE; Pava JA; Worthington JJ; Rosenbaum JF; Fava M
    J Clin Psychiatry; 1999 Apr; 60(4):221-5. PubMed ID: 10221281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius.
    Pérez V; Soler J; Puigdemont D; Alvarez E; Artigas F
    Arch Gen Psychiatry; 1999 Apr; 56(4):375-9. PubMed ID: 10197835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 1: predictors of clinical response in fluoxetine-resistant depression.
    Papakostas GI; Petersen T; Mischoulon D; Ryan JL; Nierenberg AA; Bottiglieri T; Rosenbaum JF; Alpert JE; Fava M
    J Clin Psychiatry; 2004 Aug; 65(8):1090-5. PubMed ID: 15323594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment approaches to major depressive disorder relapse. Part 2: reinitiation of antidepressant treatment.
    Fava M; Schmidt ME; Zhang S; Gonzales J; Raute NJ; Judge R
    Psychother Psychosom; 2002; 71(4):195-9. PubMed ID: 12097784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial.
    Akhondzadeh S; Jafari S; Raisi F; Nasehi AA; Ghoreishi A; Salehi B; Mohebbi-Rasa S; Raznahan M; Kamalipour A
    Depress Anxiety; 2009; 26(7):607-11. PubMed ID: 19496103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder.
    Thase ME; Corya SA; Osuntokun O; Case M; Henley DB; Sanger TM; Watson SB; Dubé S
    J Clin Psychiatry; 2007 Feb; 68(2):224-36. PubMed ID: 17335320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial.
    Perry EB; Berman RM; Sanacora G; Anand A; Lynch-Colonese K; Charney DS
    J Clin Psychiatry; 2004 Feb; 65(2):238-43. PubMed ID: 15003079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Timing of onset of antidepressant response with fluoxetine treatment.
    Nierenberg AA; Farabaugh AH; Alpert JE; Gordon J; Worthington JJ; Rosenbaum JF; Fava M
    Am J Psychiatry; 2000 Sep; 157(9):1423-8. PubMed ID: 10964858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous administration of adenosine triphosphate and phosphocreatine combined with fluoxetine in major depressive disorder: protocol for a randomized, double-blind, placebo-controlled pilot study.
    Chen Y; Cao X; Zang W; Tan S; Ou CQ; Shen X; Gao T; Zhao L
    Trials; 2019 Jan; 20(1):34. PubMed ID: 30626424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study.
    Fava M; Rosenbaum JF; McGrath PJ; Stewart JW; Amsterdam JD; Quitkin FM
    Am J Psychiatry; 1994 Sep; 151(9):1372-4. PubMed ID: 8067495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression.
    Corya SA; Williamson D; Sanger TM; Briggs SD; Case M; Tollefson G
    Depress Anxiety; 2006; 23(6):364-72. PubMed ID: 16710853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venlafaxine extended-release: a review of its use in the management of major depression.
    Wellington K; Perry CM
    CNS Drugs; 2001; 15(8):643-69. PubMed ID: 11524036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. When should a trial of fluoxetine for major depression be declared failed?
    Quitkin FM; Petkova E; McGrath PJ; Taylor B; Beasley C; Stewart J; Amsterdam J; Fava M; Rosenbaum J; Reimherr F; Fawcett J; Chen Y; Klein D
    Am J Psychiatry; 2003 Apr; 160(4):734-40. PubMed ID: 12668363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NEO-FFI factor scores as predictors of clinical response to fluoxetine in depressed outpatients.
    Petersen T; Papakostas GI; Bottonari K; Iacoviello B; Alpert JE; Fava M; Nierenberg AA
    Psychiatry Res; 2002 Jan; 109(1):9-16. PubMed ID: 11850046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and response time to sertraline versus fluoxetine in the treatment of unipolar major depressive disorder.
    Suri RA; Altshuler LL; Rasgon NL; Calcagno JL; Frye MA; Gitlin MJ; Hwang S; Zuckerbrow-Miller J
    J Clin Psychiatry; 2000 Dec; 61(12):942-6. PubMed ID: 11206600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.